公开(公告)号：US20150302143A1

公开(公告)日：2015-10-22

申请号：US14440582

申请日：2013-11-04

申请人： GENOMIC HEALTH, INC.

发明人： Yan Ma ,  Kunbin Qu ,  Mei-Lan Liu ,  Ranjana Ambannavar ,  James Stephans ,  John Pan

IPC分类号： G06F19/18 ,  G06F19/22 ,  G06F19/00 ,  C12Q1/68

CPC分类号： G06F19/18 ,  C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/16 ,  G06F19/22 ,  G16H50/20

摘要： The present invention relates to gene fusions and alternative spliced junctions associated with breast cancer. The present invention also relates to novel methods of identifying gene fusions and alternative spliced junctions in RNA sequencing data. The present invention further relates to predicting prognosis of a breast cancer patient based on the number of gene fusion events.

摘要翻译： 本发明涉及与乳腺癌相关的基因融合体和选择性剪接点。 本发明还涉及鉴定RNA测序数据中的基因融合和可变剪接的新方法。 本发明还涉及基于基因融合事件的数量预测乳腺癌患者的预后。

公开(公告)号：US10169530B2

公开(公告)日：2019-01-01

申请号：US14440582

申请日：2013-11-04

申请人： GENOMIC HEALTH, INC.

发明人： Yan Ma ,  Kunbin Qu ,  Mei-Lan Liu ,  Ranjana Ambannavar ,  James Stephans

IPC分类号： G06F19/18 ,  C12Q1/6886 ,  G06F19/22 ,  G16H50/20

摘要： The present invention relates to gene fusions and alternative spliced junctions associated with breast cancer. The present invention also relates to novel methods of identifying gene fusions and alternative spliced junctions in RNA sequencing data. The present invention further relates to predicting prognosis of a breast cancer patient based on the number of gene fusion events.

公开(公告)号：US20140296085A1

公开(公告)日：2014-10-02

申请号：US14355642

申请日：2012-11-02

申请人： GENOMIC HEALTH, INC.

发明人： Joffre B. Baker ,  Dominick S. Sinicropi ,  Robert J. Pelham ,  Michael R. Crager ,  Francois Collin ,  James C. Stephans ,  Mei-Lan Liu ,  John D. Morlan ,  Kunbin Qu

IPC分类号： G06F19/18 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q1/686 ,  C12Q2600/118 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57415 ,  G01N2800/54 ,  G01N2800/56 ,  G01N2800/60 ,  G16B20/00

摘要： The present invention relates to biomarkers associated with breast cancer prognosis. These biomarkers include coding transcripts and their expression products, as well as non-coding transcripts, and are useful for predicting the likelihood of breast cancer recurrence in a breast cancer patient, The present invention also relates to a novel method of identifying intergenic sequences that correlate with a clinical outcome.

摘要翻译： 本发明涉及与乳腺癌预后相关的生物标志物。 这些生物标志物包括编码转录物及其表达产物，以及非编码转录物，并且可用于预测乳腺癌患者乳腺癌复发的可能性。本发明还涉及一种鉴定与之相关的基因间序列的新方法 具有临床结果。